Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes

ETM Dams, P Laverman, WJG Oyen, G Storm, GL Scherphof, JWM Van der Meer, FHM Corstens, OC Boerman*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    442 Citations (Scopus)

    Abstract

    Sterically stabilized liposomes are considered promising carriers of therapeutic agents because they can facilitate controlled release of the drugs, thereby reducing drug-related toxicity and/or targeted delivery of drugs. Herein, we studied the pharmacokinetics and biodistribution of repeated injections of radiolabeled polyethyleneglycol (PEG) liposomes. Weekly injections of Tc-99m-PEG liposomes dramatically influenced the circulatory half-life in rats. Biodistribution 4 h after the second dose showed a significantly reduced blood content (from 52.6 +/- 3.7 to 0.6 +/- 0.1% injected dose (ID), P <.01) accompanied by a highly increased uptake in the liver (from 8.1 +/- 0.8 to 46.2 +/- 9.8% ID, P <.01) and in the spleen (from 2.2 +/- 0.2 to 5.3 +/- 0.7%ID, P <.01). At subsequent injections the effect was less pronounced: after the fourth dose, the pharmacokinetics of the radiolabel had almost returned to normal. The same phenomenon was observed in a rhesus monkey, but not in mice. The enhanced blood clearance of the PEG liposomes also was observed in rats after transfusion of serum from rats that had received PEG liposomes 1 week earlier, indicating that the enhanced blood clearance was caused by a soluble serum factor. This serum factor was a heat-labile molecule that coeluted on a size exclusion column with a 150-kDa protein. In summary, i.v. administration of sterically stabilized PEG liposomes significantly altered the pharmacokinetic behavior of subsequently injected PEG liposomes in a time- and frequency-dependent manner. The observed phenomenon may have important implications for the repeated administration of sterically stabilized liposomes for targeted drug delivery.

    Original languageEnglish
    Pages (from-to)1071-1079
    Number of pages9
    JournalJournal of Pharmacology and Experimental Therapeutics
    Volume292
    Issue number3
    Publication statusPublished - Mar-2000

    Keywords

    • KAPOSIS-SARCOMA
    • ENCAPSULATED DOXORUBICIN
    • COMPLEMENT ACTIVATION
    • ANTITUMOR-ACTIVITY
    • CLINICAL-TRIAL
    • KUPFFER CELLS
    • PHASE-II
    • EFFICACY
    • TOXICITY
    • PHOSPHATIDYLSERINE

    Cite this